세계의 연조직 수복 시장 : 제품별, 용도별, 최종사용자별, 지역별 - 예측(2030년)

The soft tissue repair market is projected to reach USD 20.5 million by 2030 from USD 15.9 million in 2025, growing at a CAGR of 5.1 % from 2025 to 2030.

The rising demand for soft tissue repair is growing rapidly due to the increasing volume of surgeries and the growing prevalence of severe trauma injuries.

The primary objective of soft tissue repair instruments and consumables is to fortify compromised tissue or surgically address torn or damaged soft tissue structures. The steady market growth in this sector can be attributed to several key factors, including the proliferation of innovative products across various subfields of soft tissue repair, the increasing incidence of sports-related injuries among the youth demographic, and the aging population, which is more prone to orthopedic soft tissue injuries and hernias. Moreover, advancements in healthcare infrastructure, coupled with heightened government investment in health systems and rising disposable incomes, particularly in Latin America and the Asia Pacific regions, are significantly propelling market expansion. However, challenges remain that could hinder progress, such as limited insurance reimbursements, intricate regulatory landscapes, and the high costs associated with surgical interventions.

"By product, the tissue patches/meshes segment accounted for the largest market share in the soft tissue repair market in 2024."

The tissue patches/meshes segment commanded the largest share in the soft tissue repair market in 2024, primarily due to its extensive applications in hernia repair, pelvic organ prolapse, and various reconstructive procedures that necessitate the reinforcement or replacement of compromised soft tissues. The ascendancy of these products can be attributed to their structural support capabilities, reduced operative time, and improved patient outcomes. The rising adoption of both biologic and synthetic meshes, which exhibit enhanced integration with native tissues and a lower incidence of complications, has further fueled demand. Recent advancements in mesh technology, focusing on the development of lightweight, biocompatible, and absorbable polymers, have significantly bolstered their clinical acceptance and expanded their applications. Furthermore, the increasing prevalence of obesity, coupled with an aging demographic and a growing volume of surgeries requiring tissue reinforcement and reconstruction, contributes to the segment's robust growth. Moreover, the favorable reimbursement landscape for hernia and soft tissue repair procedures in developed markets enhances the adoption of patches and meshes, thereby solidifying their leading role within the product portfolio.

"By application, the skin repair segment held the third-largest market share in the soft tissue repair market in 2024."

In the context of application types within the soft tissue repair market, skin repair represents the third-largest segment. A key factor influencing this segment is the high prevalence of chronic wounds, which necessitate effective skin repair interventions, such as those for diabetic foot ulcers, pressure ulcers, and venous leg ulcers. The growing incidence of burn injuries and traumatic skin wounds further escalates the demand for advanced wound care and skin grafting solutions. Recent advancements in wound care technologies, including innovations in collagen dressings, growth factor therapies, and bioengineered skin substitutes, have markedly improved treatment efficacy. Moreover, heightened awareness among both patients and healthcare practitioners regarding the critical importance of timely wound management has played a substantial role in this market's expansion. Coupled with the increasing availability of insurance coverage for chronic wound care in many developed nations, these factors collectively contribute to the sustained growth of the skin repair segment within the broader soft tissue repair market.

"By end user, the hospitals & clinics segment had the largest market share in the soft tissue repair market in 2024."

Hospitals and clinics dominate the market share largely due to their substantial patient throughput, which drives the demand for a wide spectrum of treatments ranging from routine procedures to complex surgical interventions. These institutions are often the primary access points for acute conditions such as trauma, sports-related injuries, and other ailments that require advanced soft tissue repair techniques. Equipped with highly qualified medical personnel and sophisticated infrastructure, hospitals often feature specialized departments-such as sports medicine, general surgery, and orthopedics-that enable comprehensive diagnostic capabilities and surgical interventions. Additionally, larger hospitals and comprehensive care clinics leverage economies of scale, allowing them to procure state-of-the-art surgical products and cutting-edge technologies. Their substantial funding and established relationships with leading medical device manufacturers enhance their ability to adopt and implement innovative solutions in patient care.

"By region, Europe had the second-largest market share in the soft tissue repair market in 2024."

Europe is in the second leading position in the soft tissue repair market due to a combination of elements. A strong healthcare infrastructure backs the region, which facilitates widespread access to advanced surgical procedures and technologies. There is an unnatural need for soft tissue repair offerings brought about by the convergence of extensive age-related hernias and orthopedic diseases with a growing elderly population. European countries have strong reimbursement systems in place, along with favorable regulatory environments, which collectively encourage the uptake of innovative medical devices. The region is topped up by sustained funding for healthcare research, along with widespread adoption of early surgical techniques and the formation of leading medical device firms. The demand for soft tissue repair products in Europe has gained momentum with the increased awareness of patients and healthcare specialists regarding minimally invasive treatments and improved post-surgical results.

A breakdown of the primary participants (supply-side) for the soft tissue repair market referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
• By Designation: C-level-20%, Director Level 35%, and Others-45%
• By Region: North America-27%, Europe-25%, Asia Pacific-30%, Others-18%.

Key players in the Soft tissue repair market are Smith & Nephew (UK), Arthrex, Inc. (US), Stryker Corporation (US), Johnson & Johnson (US), Medtronic (IE), Lifenet Health, Inc. (US), Becton, Dickinson and Company (US), Integra Lifesciences Corporation (US), Organogenesis Inc. (US), Zimmer Biomet (US), Baxter International, Inc. (US), ACell Inc. (US), Tissue Regenix Group Plc (UK), Aroa Biosurgery Ltd. (NZ), Artivion Inc. (US), CONMED Corporation (US), Meril Lifesciences Pvt Ltd. (India), RTI Surgical (US), Samyang Holdings Corporation (South Korea), Acera Surgical Inc. (US), Orthocell Ltd. (Australia), Biocer Entwicklungs Gmbh (Germany), Isto Biologics (US), Betatech Medical (Turkey), and Mimedx (US)

Research Coverage:

The report analyzes the soft tissue repair market and aims to estimate the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a competitive analysis of the key players in this market, along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall soft tissue repair market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

Analysis of key drivers (increasing geriatric population and obesity rate, rising incidence of sports injuries and trauma cases, growing focus on R&D for technologically advanced soft tissue repair product manufacturing, increasing volume of surgeries) restraints (unfavorable reimbursement scenario, high cost of advanced orthodontic treatment and surgical procedures) opportunities (growing adoption of regenerative medicine and biologics in emerging economies, increasing use of combination materials for enhancing product efficacy), challenges (stringent regulatory framework, shortage of skilled surgeons and specialized facilities)

Market Penetration: The report includes extensive information on products offered by the major players in the global soft tissue repair market. It also includes various segments by product, application, end user, and region.

Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global soft tissue repair market.

Market Development: Thorough knowledge and analysis of the profitable rising markets by product, application, end user, and region.

Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global soft tissue repair market.

Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global soft tissue repair market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
    • 2.1.2.5 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS
  • 2.2.2 BOTTOM-UP APPROACH (SUPPLY-SIDE ANALYSIS)
  • 2.2.3 TOP-DOWN APPROACH (BASED ON UTILIZATION RATE AND ADOPTION PATTERN)
  • 2.2.4 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
  • 2.2.5 VOLUME ESTIMATION
• 2.3 GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 SCOPE-RELATED LIMITATIONS
  • 2.5.2 METHODOLOGY-RELATED LIMITATIONS
• 2.6 RISK ANALYSIS
• 2.7 STUDY ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SOFT TISSUE REPAIR MARKET OVERVIEW
• 4.2 SOFT TISSUE REPAIR MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: SOFT TISSUE REPAIR MARKET, BY PRODUCT AND COUNTRY (2024)
• 4.4 SOFT TISSUE REPAIR MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 SOFT TISSUE REPAIR MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing geriatric population and rising prevalence of obesity
    • 5.2.1.2 Increasing occurrence of sports injuries
    • 5.2.1.3 Rise in R&D investments and launch of technologically advanced products
    • 5.2.1.4 High volume of surgeries and advancements in regenerative technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.2.2 High cost of soft tissue repair products and surgical procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing adoption of advanced soft tissue repair products in emerging economies
    • 5.2.3.2 Rising use of combination materials for enhancing product efficacy
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory framework
    • 5.2.4.2 Requirement of skilled personnel for effective use of soft tissue repair products
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 ROLE IN ECOSYSTEM
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF SYNTHETIC MESHES, BY REGION, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE FOR SOFT TISSUE REPAIR PRODUCTS, BY TYPE, 2023
  • 5.4.3 AVERAGE SELLING PRICE TREND OF SOFT TISSUE REPAIR PRODUCTS, BY KEY PLAYER, 2022-2024
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 PATENT ANALYSIS
  • 5.6.1 PATENT PUBLICATION TRENDS FOR SOFT TISSUE REPAIR MARKET
  • 5.6.2 TOP APPLICANTS (COMPANIES) OF SOFT TISSUE REPAIR PATENTS
  • 5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN SOFT TISSUE REPAIR MARKET
  • 5.6.4 LIST OF MAJOR PATENTS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Stem cell and regenerative therapies
    • 5.8.1.2 Suture anchors and fixation devices
  • 5.8.2 ADJACENT TECHNOLOGIES
    • 5.8.2.1 3D bioprinting and tissue engineering
    • 5.8.2.2 Regenerative medicine and biologics
  • 5.8.3 COMPLEMENTARY TECHNOLOGIES
    • 5.8.3.1 Wound closure and hemostatic devices
• 5.9 TRADE ANALYSIS
  • 5.9.1 IMPORT DATA FOR HS CODE 300640, 2019-2023
  • 5.9.2 EXPORT DATA FOR HS CODE 300640, 2019-2023
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY FRAMEWORK
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
      • 5.11.1.3.3 India
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East
    • 5.11.1.6 Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 BARGAINING POWER OF SUPPLIERS
  • 5.12.5 THREAT OF SUBSTITUTES
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 TREATMENT OF CHRONIC SHOULDER INSTABILITY USING REGENETEN BIOINDUCTIVE IMPLANTS
  • 5.15.2 TREATMENT OF INCISIONAL HERNIA USING PARIETEX COMPOSITE VENTRAL PATCHES BY MEDTRONIC
  • 5.15.3 HEALING CHRONIC DIABETIC FOOT ULCERS WITH BILAYER WOUND MATRIX
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 REIMBURSEMENT SCENARIO ANALYSIS
• 5.18 END-USER EXPECTATIONS
• 5.19 IMPACT OF AI/GEN AI ON SOFT TISSUE REPAIR MARKET
• 5.20 IMPACT OF 2025 US TARIFF ON SOFT TISSUE REPAIR MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON END-USE INDUSTRIES

6 SOFT TISSUE REPAIR MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 TISSUE PATCHES/MESHES
  • 6.2.1 SYNTHETIC MESHES
    • 6.2.1.1 Cost-effectiveness and minimal risk of donor-to-host infectious disease transmission to aid market growth
  • 6.2.2 BIOLOGICAL MESHES
    • 6.2.2.1 Allografts
      • 6.2.2.1.1 Better biocompatibility to fuel adoption in surgeries and organ transplants
    • 6.2.2.2 Xenografts
      • 6.2.2.2.1 Availability in multiple sizes to make xenografts more viable alternative in soft tissue repair procedures
  • 6.2.3 FIXATION PRODUCTS
    • 6.2.3.1 Suture anchors
      • 6.2.3.1.1 Increasing number of soft tissue injuries and growing need for surgeries to augment segment growth
    • 6.2.3.2 Interference screws
      • 6.2.3.2.1 Rise in injuries among geriatric population and availability of biodegradable interference screws to drive segment
    • 6.2.3.3 Other fixation products
• 6.3 LAPAROSCOPIC INSTRUMENTS
  • 6.3.1 QUICKER RECOVERY TIME, DECREASED PAIN, LOWER INFECTION RATES, AND REDUCED DISEASE RECURRENCE TO DRIVE MARKET
• 6.4 OTHER PRODUCTS

7 SOFT TISSUE REPAIR MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 HERNIA REPAIR
  • 7.2.1 RISING ADOPTION OF TENSION-FREE HERNIA REPAIR PROCEDURES TO FUEL MARKET GROWTH
• 7.3 SKIN REPAIR
  • 7.3.1 RISING CASES OF BURN INJURIES TO SUPPORT MARKET GROWTH
• 7.4 ORTHOPEDIC SOFT TISSUE REPAIR
  • 7.4.1 INCREASING SPORTS INJURIES AMONG ATHLETES AND RISING INCIDENCE OF ARTHRITIS IN ELDERLY TO FAVOR MARKET GROWTH
• 7.5 DENTAL SOFT TISSUE REPAIR
  • 7.5.1 RISING NUMBER OF PREVENTIVE AND COSMETIC DENTAL PROCEDURES TO PROPEL MARKET GROWTH
• 7.6 BREAST RECONSTRUCTION
  • 7.6.1 PREVALENCE OF BREAST CANCER AND INCREASING PATIENTS UNDERGOING MASTECTOMY TO AUGMENT MARKET GROWTH
• 7.7 DURAL REPAIR
  • 7.7.1 RISING PREVALENCE OF NEUROVASCULAR DISORDERS TO DRIVE MARKET
• 7.8 VAGINAL SLINGS
  • 7.8.1 INCREASED OCCURRENCE OF STRESS-INDUCED URINARY INCONTINENCE (SUI) TO BOOST MARKET GROWTH
• 7.9 OTHER APPLICATIONS

8 SOFT TISSUE REPAIR MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINICS
  • 8.2.1 RISING NUMBER OF REIMBURSED IN-PATIENT PROCEDURES TO DRIVE MARKET
• 8.3 AMBULATORY SURGICAL CENTERS
  • 8.3.1 QUICKER CONSULTATION SERVICES AND MINIMAL PATIENT STAY TO FUEL MARKET GROWTH
• 8.4 OTHER END USERS

9 SOFT TISSUE REPAIR MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American soft tissue repair market during forecast period
  • 9.2.3 CANADA
    • 9.2.3.1 High healthcare expenditure and favorable public & private funding to support market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Advanced healthcare infrastructure and favorable surgical reimbursement to propel market growth
  • 9.3.3 FRANCE
    • 9.3.3.1 Well-established healthcare system and high geriatric population to boost market growth
  • 9.3.4 UK
    • 9.3.4.1 Increasing hernia repair and cardiovascular surgeries to stimulate market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Favorable government initiatives and high demand for surgical interventions to support market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Increasing healthcare budget and rising focus on local medical product manufacturing to drive market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 JAPAN
    • 9.4.2.1 Strong healthcare system and high geriatric population to favor market growth
  • 9.4.3 CHINA
    • 9.4.3.1 Increasing number of hospitals and rising focus on healthcare policy reforms to stimulate market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Greater healthcare awareness and increased government support to aid market growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing government support and rising healthcare expenditure to support market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Advanced healthcare infrastructure and adoption of minimally invasive surgical technologies to fuel market growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Strong public healthcare system and favorable government-led initiatives to aid market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Increased focus on healthcare modernization and surgical innovation to favor market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 ADVANCED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT POLICIES TO DRIVE MARKET
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 9.7 GCC COUNTRIES
  • 9.7.1 FOCUS ON MEDICAL TOURISM AND AVAILABILITY OF ADVANCED SURGICAL PROCEDURES TO AID MARKET GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SOFT TISSUE REPAIR MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Application footprint
    • 10.5.5.5 End-user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of startups/SMEs
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 R&D EXPENDITURE
• 10.9 BRAND/PRODUCT COMPARISON
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES
  • 10.10.2 DEALS
  • 10.10.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 ARTHREX, INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 MnM view
      • 11.1.1.3.1 Right to win
      • 11.1.1.3.2 Strategic choices
      • 11.1.1.3.3 Weaknesses & competitive threats
  • 11.1.2 SMITH & NEPHEW PLC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Expansions
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 BECTON, DICKINSON AND COMPANY (BD)
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 MnM view
      • 11.1.4.3.1 Right to win
      • 11.1.4.3.2 Strategic choices
      • 11.1.4.3.3 Weaknesses & competitive threats
  • 11.1.5 STRYKER
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 MnM view
      • 11.1.5.3.1 Right to win
      • 11.1.5.3.2 Strategic choices
      • 11.1.5.3.3 Weaknesses & competitive threats
  • 11.1.6 MEDTRONIC
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
      • 11.1.6.3.3 Other developments
  • 11.1.7 ZIMMER BIOMET
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Deals
  • 11.1.8 INTEGRA LIFESCIENCES CORPORATION
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
  • 11.1.9 ARTIVION, INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 ORGANOGENESIS INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
  • 11.1.11 LIFENET HEALTH
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 BAXTER
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 TISSUE REGENIX
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
  • 11.1.14 CONMED CORPORATION
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
  • 11.1.15 MERIL LIFE SCIENCES PVT. LTD.
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
  • 11.1.16 RTI SURGICAL
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 SAMYANG HOLDINGS CORPORATION
  • 11.2.2 AROA BIOSURGERY LIMITED
  • 11.2.3 ACERA SURGICAL INC.
  • 11.2.4 ORTHOCELL LTD.
  • 11.2.5 ACELL, INC.
  • 11.2.6 BIOCER ENTWICKLUNGS-GMBH
  • 11.2.7 ISTO BIOLOGICS
  • 11.2.8 BETATECH MEDICAL
  • 11.2.9 MIMEDX GROUP, INC.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS